Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Search
Duluth
Duluth
Angels Initiative in South Africa
Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Investing in our people University of Medicine Excellence
Almost one thousand of our employees have graduated from a program developed together with Harvard Medical School’s Executive Education.
Inhaler Discussion Guide
Boehringer Ingelheim China for a green future
Boehringer Ingelheim China for a green future: China employees were collecting trash on Nanhui Zui Beach for a greener future
The METAmorphosis
At Boehringer Ingelheim’s META offices in the Middle East, Turkey and Africa all offices in the region are already free of single-use plastic.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Microbial expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins, complementing mammalian cell processes for larger proteins like monoclonal antibodies.
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Digital Transformation Within Our Global IT
Technology is at the heart of our strategy.
Grow Your Skills
Great things in business are never done by one person; they’re done by a team of people
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
ACR19 Autoimmune Trial
ACR Congress 2019 abstract analysing a subgroup of patients with autoimmune diseases in the INBUILD® trial of nintedanib in patients with PF-ILF
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
Powered By Our People – A Global IT Community
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Empowering smallholder farmers
The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
Netherton syndrome (NS)
Information on Netherton syndrome (NS), a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.